New Pill for People with Type 2 Diabetes

37

The Upjohn Company has recently released a new glyburide tablet that is designed to improve absorption and dosing flexibility for people with Type 2 diabetes.

The Glynase PresTab tablet is a patented 3 mg glyburide tablet that divides easily in two with the press of a finger. This new design allows diabetes patients to measure their prescribed daily dosage easily and accurately, with a consistent available potency between 90% and 100%.

According to the Upjohn Company, Glynase PresTab’s improved potency allows patients to take a dosage lower than the already available Micronase glyburide tablet and still expect the same results. The Upjohn Company recommends that patients have their dosage readjusted by a doctor before switching from Micronase or other hypoglycemic agents to Glynase PresTab.

Comments

comments

This post authored by
Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.